News

Almirall + HitGen = novel oral compounds for AD

Published on 07/06/2019

Almirall and HitGen entered in a multi-target research collaboration to develop novel oral chemical entities for patients suffering from moderate to severe atopic dermatitis

READ MORE

You are part of our success: AlmirallShare results

Published on 11/02/2019

More than 450 scientists subscribed and over 170 different proposals received

READ MORE

Digital + omics = unprecedented target-disease associations

Published on 23/01/2019

Partnership between Almirall, S.A. and Barcelona Supercomputing Center (BSC) to identify novel targets to treat dermatological diseases

READ MORE

SilicoDerm: new modeling techniques for dermatological research

Published on 31/10/2018

SilicoDerm computational methodologies will facilitate the identification of active compounds for the treatment of inflammatory skin diseases

READ MORE

Almirall + Evotec = first-in-class dermatological therapies

Published on 30/10/2018

Almirall S.A. and Evotec AG have entered into a research collaboration to discover and develop first-in-class therapies for debilitating dermatology diseases

READ MORE

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our policy of cookies, click on the link for more information.

ACEPTAR
Aviso de cookies